Royalty Pharma plc Class A Ordinary Shares
Symbol: RPRX (NASDAQ)
36.80
▲ (0.28%) 0.101
Company Description:
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Key Stats
- Today's Open: $36.58
- Today's High: $37.316
- Today's Low: $36.185
- Today's Volume: 3.65M
- Yesterday Close: $36.7
- Yesterday High: $36.94
- Yesterday Low: $35.97
- Yesterday Volume: 3.66M
- Last Min Volume: 100
- Last Min High: $37.316
- Last Min Low: $36.801
- Last Min VWAP: $37.15025
Company Profile
- Name: Royalty Pharma plc Class A Ordinary Shares
- Website: https://www.royaltypharma.com
- Listed Date: 2020-06-16
- Location: NEW YORK, NY
- Market Status: Active
- CIK Number: 0001802768
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $15.72B
- Round Lot: 100
- Outstanding Shares: 432.29M
- Asset Type: CS
RECENT FILINGS FOR RPRX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-03 | 424B2 | View |
| 2025-09-03 | FWP | View |
| 2025-09-02 | 424B2 | View |
| 2025-09-02 | POSASR | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | 8-K | View |
| 2025-08-13 | SCHEDULE 13G | View |
| 2025-08-11 | 4 | View |
| 2025-08-11 | 144 | View |
| 2025-08-08 | 4 | View |
| 2025-08-08 | 4 | View |
| 2025-08-08 | 4 | View |
| 2025-08-08 | 4 | View |
| 2025-08-08 | 4 | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-08-05 | SCHEDULE 13G/A | View |
| 2025-07-31 | 4 | View |
| 2025-07-31 | 4 | View |
| 2025-07-25 | 3 | View |